Cargando…

Emerging Cellular Therapies for Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most common type of malignant primary brain cancer in adults. It is composed of highly malignant cells that display metastatic and angiogenic characteristics, making it resistant to current first-line chemotherapy with temozolomide, an alkylating agent. Despite m...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Paul J, Tubbs, R. Shane, Oskouian, Rod J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947919/
https://www.ncbi.nlm.nih.gov/pubmed/29755901
http://dx.doi.org/10.7759/cureus.2305
_version_ 1783322462669242368
author Choi, Paul J
Tubbs, R. Shane
Oskouian, Rod J
author_facet Choi, Paul J
Tubbs, R. Shane
Oskouian, Rod J
author_sort Choi, Paul J
collection PubMed
description Glioblastoma multiforme (GBM) is the most common type of malignant primary brain cancer in adults. It is composed of highly malignant cells that display metastatic and angiogenic characteristics, making it resistant to current first-line chemotherapy with temozolomide, an alkylating agent. Despite many years of research, GBM remains poorly responsive to multiple available therapies, giving GBM patients, who receive the conventional combination of chemoradiotherapies and surgical resection, a dismal prognosis. There is growing evidence that the conventional systemic chemotherapeutic agents for GBM are ineffective in improving the disease progression. We aim to explore the emerging cellular therapies which may play a significant role in treating GBM.
format Online
Article
Text
id pubmed-5947919
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-59479192018-05-13 Emerging Cellular Therapies for Glioblastoma Multiforme Choi, Paul J Tubbs, R. Shane Oskouian, Rod J Cureus Neurology Glioblastoma multiforme (GBM) is the most common type of malignant primary brain cancer in adults. It is composed of highly malignant cells that display metastatic and angiogenic characteristics, making it resistant to current first-line chemotherapy with temozolomide, an alkylating agent. Despite many years of research, GBM remains poorly responsive to multiple available therapies, giving GBM patients, who receive the conventional combination of chemoradiotherapies and surgical resection, a dismal prognosis. There is growing evidence that the conventional systemic chemotherapeutic agents for GBM are ineffective in improving the disease progression. We aim to explore the emerging cellular therapies which may play a significant role in treating GBM. Cureus 2018-03-11 /pmc/articles/PMC5947919/ /pubmed/29755901 http://dx.doi.org/10.7759/cureus.2305 Text en Copyright © 2018, Choi et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Choi, Paul J
Tubbs, R. Shane
Oskouian, Rod J
Emerging Cellular Therapies for Glioblastoma Multiforme
title Emerging Cellular Therapies for Glioblastoma Multiforme
title_full Emerging Cellular Therapies for Glioblastoma Multiforme
title_fullStr Emerging Cellular Therapies for Glioblastoma Multiforme
title_full_unstemmed Emerging Cellular Therapies for Glioblastoma Multiforme
title_short Emerging Cellular Therapies for Glioblastoma Multiforme
title_sort emerging cellular therapies for glioblastoma multiforme
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947919/
https://www.ncbi.nlm.nih.gov/pubmed/29755901
http://dx.doi.org/10.7759/cureus.2305
work_keys_str_mv AT choipaulj emergingcellulartherapiesforglioblastomamultiforme
AT tubbsrshane emergingcellulartherapiesforglioblastomamultiforme
AT oskouianrodj emergingcellulartherapiesforglioblastomamultiforme